logo
Kern County economic summit premieres new innovations and tariff discussions

Kern County economic summit premieres new innovations and tariff discussions

Yahoo02-05-2025

BAKERSFIELD, Calif. (KGET) — The Kern County Economic Summit was held at Cal State Bakersfield where industry leaders and economists joined to discuss the changing business landscape.
New innovations were shown, job growth and reduction analyzed, and new industries shared their faces in Kern.The 2025 summit marked the first year back in-person since the pandemic, and featured multiple panelists as well as speakers that spoke about healthcare, education, tariffs, and more.
'It's an opportunity for the community to come together and learn about the economy, learn about healthcare, education, and even innovation into the future,' said Janelle Capra, CEO and President of the Greater Bakersfield Chamber.
Two CSUB economists spoke at the Summit: Dr. Richard Gearhart and Dr. Nyakundi Michieka.
Gearhart talked about our job population and that most of the industries are growing besides oil and gas.
'We've seen growth in every economic sector except for mining, and we've seen considerable employment growth compared to 2010. We have 160,000 more people with jobs here in Kern County and 10,000 fewer people without jobs,' said Gearhart.
Gearhart also spoke on tariffs and how they are a threat to Kern's economy.
'Tariffs in general are a bad idea, they're a consumer tax, it's equivalent to a sales tax, and we just had an 18% tax imposed on every consumer here in the United States,' said Gearhart.
Gearhart says tariffs affect two major industries in Kern: agriculture and warehousing.
Tariffs in 2018 caused the agriculture sector to need a $30 billion federal bail out just to keep revenues up.
'Consumers are worried about shelves that are gonna go empty, consumers are worried about inflation. The federal reserve has suggested that we could see inflation of nearly 10% from tariffs. Along with reduced economic growth,' said Gearhart.
Dr. Nyakundi Michieka, another CSUB economist, said that despite a public perception, California's population isn't going down.
'The population from 2019 to 2024 stayed relatively the same, but there was little bit of a dip in growth,' said Dr. Michieka.
He also said that wasn't the case for Kern County.
'Kern County is one of the counties that saw an increase in population,' said Dr. Michieka.
There were also panels on education, healthcare, along with speakers for new businesses like Stratolaunch– a rocket company, Pacific Steel Group, and the Hard Rock Hotel and Casino in Tejon.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

17 News' political analysts break down Trump and Musk feud
17 News' political analysts break down Trump and Musk feud

Yahoo

timea day ago

  • Yahoo

17 News' political analysts break down Trump and Musk feud

BAKERSFIELD, Calif. (KGET) — Some Democrats are calling the online feud between President Donald Trump and Elon Musk a messy breakup…coining it, 'the Real Housewives of Pennsylvania Ave.' 17 News political analysts, Neel Sannappa and Cathy Abernathy, joined 17 News at 5 to discuss the jabber between Musk and Trump. Watch the full interview in the player above for the full 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst
‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst

Business Insider

timea day ago

  • Business Insider

‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst

Although Snowflake (SNOW) shares have already climbed over 35% this year, UBS believes that the software stock still has more room to grow. Following Snowflake's annual Summit in San Francisco, UBS upgraded the stock from Neutral to Buy and raised its price target from $210 to $265. Despite being late to the upgrade, analysts led by five-star rated Karl Keirstead said that Snowflake's performance has only started improving in the last few quarters, and that the broader AI-related investment cycle is just beginning. Confident Investing Starts Here: Indeed, UBS noted that Snowflake is one of the companies benefiting from the need for 'AI-ready' data, along with Palantir (PLTR) and Databricks. The analysts also pointed out that more software companies like Salesforce (CRM), ServiceNow (NOW), and SAP (SAP) are moving into the data space, which they see as evidence of the growing demand for data. As a result, UBS believes that Snowflake investors haven't fully priced in this growth potential yet and that there's still time to invest before the full AI boom happens. Separately, Morgan Stanley kept its Equal-weight rating and $200 price target despite Snowflake's strengths in data security, ease of use, and multi-cloud capabilities. While the analysts led by five-star rated Keith Weiss praised the company's role in secure AI integration, they remain cautious about the stock's high valuation, which sits at about 55 times the expected free cash flow for 2026. Nevertheless, it is worth mentioning that Snowflake's expansion into data engineering and AI has significantly increased its market opportunity and might justify its premium valuation. Is SNOW a Good Buy Right Now? Overall, analysts have a Strong Buy consensus rating on SNOW stock based on 34 Buys, six Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average SNOW price target of $225.03 per share implies 6.4% upside potential.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.

Business Upturn

timea day ago

  • Business Upturn

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ('Summit' or the 'Company') (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 30, 2025, Summit issued a press release 'announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]' Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause. On this news, Summit's stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP [email protected] 646-581-9980 ext. 7980

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store